In conclusion, our results provide new arguments on the pharmacological effectiveness of TRPV1 antagonist instillation against DED-induced sensory abnormalities and anxiety, opening a new avenue for the repositioning of this class of molecule as a potential analgesic treatment of patients suffering from chronic DED. Here, TRPV1 is linked to Anxiety.